Compare M&T Bank Corporation (MTB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? M&T Bank Corporation trades at $222.43 (market cap $31.42B), while State Street SPDR S&P Biotech ETF trades at $149.65 (market cap $10.11B). The key difference: M&T Bank Corporation is far larger — about 3.1× State Street SPDR S&P Biotech ETF's market cap, and M&T Bank Corporation pays a 2.76% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold M&T Bank Corporation for 100 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| MTB | XBI | |
|---|---|---|
Market Cap | $31.42B | $10.11B |
Volume | 1,438,219 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $254.09 | $169.55 |
52-Week Low | $178.63 | $104.99 |
Typical Hold Time | 100 Days | 37 Days |
Enterprise Value | $47.77B | — |
Dividend Yield | 2.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank Corporation (MTB) trades at $216.6, down 0.98% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The bank maintains strong profitability with a 30.85% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights loan growth, AI investments, and a new branch opening, while the company declared a $1.50 dividend payable in September 2026.
The outlook is mixed: analyst consensus is a 'Buy' with a $258.92 price target implying 19.5% upside, but technical weakness and a high proportion of 'Hold' ratings suggest caution. Key risks include volatile cash flows, with a net outflow of $2.01B in 2025, and sensitivity to interest rate changes. Earnings momentum from loan growth and technology investments supports potential recovery.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
